Evolus Dermal Filler Evolysse Lift Meets Primary Endpoint, Demonstrates Superiority To Restylane-L At 6 Months; Shows Statistically Significant Improvement In Nasolabial Fold Severity Compared To Restylane-L At All Timepoints Over 12 Months

5/20/24 8:31:57 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $EOLS alert in real time by email

Get the next $EOLS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$EOLS

Date	Price Target	Rating	Analyst
1/29/2024	$10.00 → $16.00	Equal Weight → Overweight	Barclays
6/23/2022	$18.00	Buy	Needham
5/12/2022	$8.00 → $10.00	Underweight → Equal Weight	Barclays
1/20/2022	$11.00	Hold → Buy	Truist
11/3/2021	$22.00 → $15.00	Buy	HC Wainwright & Co.

More analyst ratings

$EOLS
Financials

Live finance-specific insights

Evolus to Report Third Quarter Financial Results on November 6, 2024
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2024 financial results on Wednesday, November 6, 2024, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a telephonic r
10/23/24 8:00:00 AM ET
$EOLS
Biotechnology: Pharmaceutical Preparations
Health Care
Evolus to Report Second Quarter Financial Results on July 31, 2024
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2024 financial results on Wednesday, July 31, 2024, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a telephonic
7/17/24 8:00:00 AM ET
$EOLS
Biotechnology: Pharmaceutical Preparations
Health Care
Evolus Reports First Quarter 2024 Results and Provides Business Update
Q1 2024 Net Revenue of $59.3 Million, Up 42% from Q1 2023 Non-GAAP Loss from Operations of $0.9 Million, on Track to Non-GAAP Profitability1 in Q4 2024 and Full Year 2025 U.S. Clinical Trials Completed for Evolysse® Lift and Smooth fillers, FDA Submission Expected within Next 90 Days Reaffirms Full-Year 2024 Net Revenue Guidance of $255 Million to $265 Million, Representing a 31% Growth Rate at the Top End Remains on Track to Achieve Projected Total Net Revenue Goal of At Least $700 Million by 2028 Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the first quarter
5/7/24 4:05:00 PM ET
$EOLS
Biotechnology: Pharmaceutical Preparations
Health Care

Evolus to Participate in Stifel 2024 Healthcare Conference
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the Stifel Healthcare Conference in New York City on Tuesday, November 19 at 10:55 AM ET. The presentation can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available for 90 days after the date of the presentation. About Evolus, Inc. Evolus (NASDAQ:EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. O
11/1/24 8:00:00 AM ET
$EOLS
Biotechnology: Pharmaceutical Preparations
Health Care
Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the EU Medical Device Regulation (MDR) certification was received for four unique injectable hyaluronic acid (HA) gels under the brand name Estyme® (pronounced "esteem"), branded as Evolysse™ in the U.S. market. This certification marks a key regulatory milestone for Evolus, enabling it to commercially enter the dermal filler segment and doubling its addressable market outside the U.S. to $1.8 billion1. The CE Mark certification, through the new MDR process represents more stringent requirements, designed to ensure the safety, efficacy, and quality of
10/31/24 2:02:00 PM ET
$EOLS
Biotechnology: Pharmaceutical Preparations
Health Care
Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers
Achieves 2 Million Jeuveau® Redemptions Anticipates Launch of Club Evolus™, the first consumer membership program by a neurotoxin manufacturer, on November 4, 2024 Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it recently surpassed one million enrolled consumers and completed the two-millionth Jeuveau® redemption in its Evolus Rewards™ patient loyalty program. "The achievement of these milestones underscores the success of our strategy to democratize beauty and make aesthetics accessible to a new generation of consumers," said David Moatazedi, President and Chief Executive Officer. "Our easy
10/29/24 8:00:00 AM ET
$EOLS
Biotechnology: Pharmaceutical Preparations
Health Care

Evolus Announces Appointment of Albert G. White III to Board of Directors
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes
7/1/24 8:00:00 AM ET
$COO
$EOLS
Ophthalmic Goods
Health Care
Biotechnology: Pharmaceutical Preparations
Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Nareg Sagherian has joined the Company as Vice President, Head of Global Investor Relations and Corporate Communications. In this role, Nareg will be responsible for interacting with current and prospective investors and managing a strategic investor relations and corporate communications program. Nareg will report to Sandra Beaver, Chief Financial Officer of Evolus. "I am thrilled to welcome Nareg to our team," said Sandra Beaver, Chief Financial Officer of Evolus. "Nareg's unique experience will enable him to drive a successful investor relati
1/4/24 4:05:00 PM ET
$EOLS
Biotechnology: Pharmaceutical Preparations
Health Care
Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer
Industry Leader Brings 20+ Years of Cosmetic Expertise to the Performance Beauty Category Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, has named Ms. Tomoko Yamagishi-Dressler as Chief Marketing Officer (CMO), effective today. Yamagishi-Dressler is an accomplished executive with more than two decades of established excellence leading omnichannel marketing for global beauty companies. A true strategist, Yamagishi-Dressler has successfully driven profitable business growth and increased equity for an iconic portfolio of industry brands. This press release features multimedia. View the full release here: https:
8/21/23 8:45:00 AM ET
$EOLS
Biotechnology: Pharmaceutical Preparations
Health Care

Evolus Dermal Filler Evolysse Lift Meets Primary Endpoint, Demonstrates Superiority To Restylane-L At 6 Months; Shows Statistically Significant Improvement In Nasolabial Fold Severity Compared To Restylane-L At All Timepoints Over 12 Months

Chat with this insight

Recent Analyst Ratings for $EOLS

$EOLS Financials

Live finance-specific insights

Evolus to Report Third Quarter Financial Results on November 6, 2024

Evolus to Report Second Quarter Financial Results on July 31, 2024

Evolus Reports First Quarter 2024 Results and Provides Business Update

$EOLS SEC Filings

SEC Form 10-Q filed by Evolus Inc.

Evolus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Evolus Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

$EOLS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Evolus upgraded by Barclays with a new price target

Needham initiated coverage on Evolus with a new price target

Evolus upgraded by Barclays with a new price target

$EOLS Large Ownership Changes

This live feed shows all institutional transactions in real time.

$EOLS Press Releases

Fastest customizable press release news feed in the world

$EOLS Leadership Updates

Live Leadership Updates

SEC Form SC 13G filed by Evolus Inc.

SEC Form SC 13G/A filed by Evolus Inc. (Amendment)

SEC Form SC 13G/A filed by Evolus Inc. (Amendment)

Evolus to Participate in Stifel 2024 Healthcare Conference

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

Evolus Announces Appointment of Albert G. White III to Board of Directors

Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications

Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer

$EOLS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Beaver Sandra sold $49,074 worth of shares (3,276 units at $14.98), decreasing direct ownership by 2% to 148,502 units (SEC Form 4)

Chief Marketing Officer Yamagishi-Dressler Tomoko sold $89,251 worth of shares (5,631 units at $15.85), decreasing direct ownership by 6% to 82,375 units (SEC Form 4)

Director White Albert G Iii was granted 23,014 shares (SEC Form 4)

$EOLS Market Insights

Live Market Insights

Evolus Announces Submission Of Premarket Approval Application To The U.S. FDA For First Two Evolysse Dermal Filler Products

Cantor Fitzgerald Reiterates Overweight on Evolus

Evolus Expands International Presence With Launch Of Nuceiva In Spain

Recent Analyst Ratings for
$EOLS

$EOLS
Financials

$EOLS
SEC Filings

$EOLS
Analyst Ratings

$EOLS
Large Ownership Changes

$EOLS
Press Releases

$EOLS
Leadership Updates

$EOLS
Insider Trading

$EOLS
Market Insights